Macular Telangiectasia Type 2: Understanding and Protecting Your Central Vision
What Is Macular Telangiectasia Type 2
MacTel type 2 is a disease that affects the macula, the small central area of the retina responsible for sharp, detailed vision. It involves changes to the tiny blood vessels surrounding the fovea, which is the very center of the macula, and also causes the gradual loss of specialized cells that support retinal health.
Although MacTel type 2 was once thought to be primarily a blood vessel disease, research has since revealed that it is largely neurodegenerative in nature. This means the disease involves the slow breakdown of specialized cells called Muller cells, which play a critical role in keeping the retina healthy. As these cells are lost, the retinal tissue in the macula begins to thin and, in some cases, develop scar tissue.
As the disease progresses, the abnormal blood vessels around the fovea may begin to leak fluid or blood. In some cases, new abnormal blood vessels grow beneath the retina, a complication known as macular neovascularization. Leaking from these vessels can cause the macula to swell, blurring central vision. Over time, tissue in the fovea may thin significantly or scar, leading to a loss of fine detail vision.
MacTel type 2 does not affect peripheral vision and does not typically lead to complete blindness. However, the loss of central vision can progress over a period of ten to twenty years and significantly impact daily activities such as reading, driving, and recognizing faces.
MacTel type 2 is sometimes confused with age-related macular degeneration or diabetic macular edema because all three conditions involve the macula. The key difference is the underlying cause. MacTel type 2 stems from Muller cell degeneration and changes in the small blood vessels at the fovea, while age-related macular degeneration involves drusen deposits and a different pattern of cell damage. Specialized imaging tests allow a retinal specialist to distinguish between these conditions accurately.
Who Is at Risk
MacTel type 2 can affect a wide range of adults, but certain factors make some people more likely to develop it. Because the disease often causes no symptoms in its early stages, many cases go undetected without regular eye examinations.
MacTel type 2 most often appears in middle-aged adults, typically in people over the age of 40. Both men and women develop the condition, though some studies suggest a slight tendency toward women. The condition affects both eyes in most patients, though it does not always progress at the same rate in each eye.
The true prevalence of MacTel type 2 has long been underestimated, largely because early stages produce no noticeable symptoms. Research suggests the condition may affect roughly one in one thousand adults aged 40 and older. Many individuals are living with this disease without knowing it, which makes routine dilated eye examinations especially important.
Certain systemic health conditions appear to be associated with a higher likelihood of developing MacTel type 2. Studies suggest that up to 45 percent of patients with MacTel have at least one systemic condition. The most commonly associated conditions include:
- Diabetes
- Hypertension (high blood pressure)
- Obesity
- Cardiovascular disease
Managing these underlying health conditions is an important part of overall care for patients with MacTel type 2.
MacTel type 2 affects both eyes in most cases, but the two eyes often progress at different rates. One eye may show more advanced changes while the other remains at an earlier stage. This asymmetry can make the condition harder to notice on your own, because the less affected eye may compensate for the other, masking changes in central vision until the disease is more advanced.
Symptoms and Warning Signs
The symptoms of MacTel type 2 develop slowly and are often subtle at first. Knowing what to look for, and when to seek prompt care, can make a meaningful difference in outcomes.
In the early stages of MacTel type 2, most people notice nothing unusual. The changes occurring in the retina are too subtle to cause obvious vision problems. This is why the condition is most often discovered during a routine dilated eye exam rather than after a patient notices something wrong.
As MacTel type 2 progresses, central vision changes become more apparent. These symptoms tend to develop gradually over months or years and may include:
- Blurring of central vision
- Distortion in which straight lines appear wavy or bent
- Difficulty reading or seeing fine details clearly
- A need for brighter lighting when reading or doing close-up work
- A gradual loss of central vision in one or both eyes
If new abnormal blood vessels develop beneath the retina, symptoms can change more quickly and noticeably. Leaking or bleeding from these vessels may cause a sudden worsening of central vision or a new area of blurriness. If you experience a sudden change in your vision, contact a retinal specialist promptly or seek emergency eye care. While MacTel type 2 generally progresses slowly, complications related to new blood vessel growth require timely evaluation and treatment.
How MacTel Type 2 Is Diagnosed
Diagnosing MacTel type 2 requires a combination of a thorough eye examination and specialized imaging. These tests allow a retinal specialist to detect the disease, assess its severity, and monitor how it changes over time.
A retinal specialist can begin to detect MacTel type 2 during a comprehensive dilated eye examination, in which drops are used to widen the pupil for a better view of the retina. The specialist may observe characteristic changes around the fovea, including a subtle reddish spot at the fovea, crystalline deposits scattered within the retinal tissue, and pigment clumping near the macula.
Optical coherence tomography, commonly called OCT, is a noninvasive imaging scan that creates detailed cross-sectional images of the retinal layers. It is one of the most important tools for diagnosing and monitoring MacTel type 2. In this condition, OCT typically reveals thinning of macular tissue, small cavities forming within the retina, and loss of photoreceptors, which are the light-sensing cells responsible for sharp vision. These findings have also helped researchers better understand the neurodegenerative nature of the disease.
Fluorescein angiography is a dye-based imaging test used to evaluate blood flow and leakage within the retina. A special dye is injected into a vein in the arm, and as it travels through the retinal vessels, a camera captures images highlighting areas of leakage and abnormal vessel growth. This test is particularly useful for identifying whether macular neovascularization has developed.
OCT angiography, or OCTA, is a newer imaging technique that maps blood flow in the retina without the need for dye injection. It can detect subtle changes in the small blood vessels surrounding the fovea and identify early neovascularization. OCTA is increasingly used alongside standard OCT to provide a more complete picture of how the disease is behaving.
Treatment Options for MacTel Type 2
Treatment for MacTel type 2 depends on the stage of the disease and whether complications such as neovascularization are present. Recent advances have introduced the first approved therapy specifically targeting this condition.
In March 2025, the FDA approved revakinagene taroretcel-lwey, marketed as ENCELTO, making it the first and only FDA-approved treatment specifically for adults with MacTel type 2. ENCELTO is an encapsulated cell-based gene therapy delivered through a small capsule, approximately the size of a grain of rice, that a retinal specialist places surgically inside the eye.
The capsule contains living cells that have been genetically modified to continuously produce and release a protein called recombinant human ciliary neurotrophic factor, known as rhCNTF. This protein reaches the retina directly, supporting the health of Muller cells and photoreceptors to slow the progression of cell loss.
Clinical trials demonstrated that ENCELTO significantly slowed the loss of macular photoreceptors over a 24-month period. In one trial protocol, treated patients experienced a 56.4 percent reduction in photoreceptor loss compared to untreated patients. A second protocol showed a 29.2 percent reduction in photoreceptor loss. Because ENCELTO is designed to slow progression rather than restore lost vision, earlier treatment, before significant cell loss has occurred, is generally expected to be more beneficial.
When MacTel type 2 develops the complication of macular neovascularization, anti-VEGF injections may be recommended. Anti-VEGF medicines block a chemical called vascular endothelial growth factor, which drives the formation of abnormal new blood vessels. By blocking this signal, the injections help reduce vessel growth, slow leakage, and decrease macular swelling.
Bevacizumab (Avastin), used off-label for eye conditions, has been studied in proliferative MacTel type 2 and has shown the ability to cause abnormal vessels to shrink and may improve visual acuity. Other anti-VEGF agents such as aflibercept (Eylea) or ranibizumab (Lucentis) may also be considered depending on the clinical situation. Your retinal specialist will discuss which option is most appropriate for you.
For patients with very early MacTel type 2, particularly those who are not yet candidates for active treatment, a retinal specialist may recommend a period of close monitoring using regular eye exams and OCT imaging. This allows the specialist to track the rate of progression and determine when intervention would be most beneficial. Regular monitoring remains an important part of care even after treatment begins.
What to Expect After Treatment
Understanding what the recovery and follow-up process looks like after treatment can help you feel more prepared and confident in your care plan.
The ENCELTO capsule is placed inside the eye during a surgical procedure performed by a retinal specialist. Because the capsule is designed to continuously release rhCNTF over time, it provides ongoing treatment without the need for repeated injections. Your specialist will schedule follow-up visits to monitor the implant and assess how the retina is responding. As with any surgical procedure involving the eye, there are risks that your specialist will thoroughly discuss with you before moving forward.
If anti-VEGF injections are needed for neovascular complications, you can expect a series of treatment visits. Injections are typically given in the office, and most patients experience mild discomfort rather than significant pain. The interval between injections varies depending on which medication is used and how the eye is responding. Your specialist will monitor your retina with regular imaging and adjust your treatment schedule accordingly.
Living Well with MacTel Type 2
A diagnosis of MacTel type 2 can feel overwhelming, but many people live active and fulfilling lives with this condition. There are practical strategies and support resources that can make a meaningful difference in your daily experience.
Because MacTel type 2 affects central vision while leaving peripheral vision intact, many people can continue functioning well in daily life, especially in the earlier stages. Several approaches can help you make the most of your remaining vision:
- Use bright, directed lighting for reading and close-up tasks
- Try large-print books, magazines, or e-readers with adjustable font size
- Use magnifying devices recommended by a low vision specialist
- Position reading material or screens to take advantage of areas where your vision is clearest
Because conditions such as diabetes, hypertension, obesity, and cardiovascular disease are commonly associated with MacTel type 2, managing your general health is an important part of your overall eye care. Keeping blood sugar, blood pressure, and weight within healthy ranges supports your broader health and may benefit your eyes as well. Coordinate closely with your primary care physician and any relevant specialists to manage these conditions effectively.
A gradual loss of central vision can affect your independence and emotional well-being. Low vision rehabilitation services can teach you new techniques for everyday tasks and help you use assistive tools effectively. Support groups for people living with macular conditions offer encouragement and practical advice from others with shared experiences. Ask your retinal specialist about referrals to low vision services or community resources that may help.
When to See a Retinal Specialist
Knowing when to schedule an appointment, and when to seek care urgently, is an important part of managing MacTel type 2 and protecting your vision.
If you are over 40, particularly if you have diabetes, hypertension, or a family history of macular disease, regular dilated eye exams are essential. Because MacTel type 2 produces no symptoms in its early stages, only a thorough examination can detect it before vision loss begins. Early detection gives you and your specialist more options for monitoring and treatment.
Contact a retinal specialist promptly if you notice any of the following:
- New or worsening blurriness in your central vision
- Distortion in which straight lines appear wavy or bent
- Difficulty reading even with good lighting
- A dark or blank spot in the center of your visual field
If you experience a sudden loss of vision, a rapid increase in floaters, or flashes of light, seek immediate care from a retinal specialist or visit an emergency room. While these symptoms may not always be related to MacTel type 2, they can signal other serious retinal conditions that require urgent attention.
Frequently Asked Questions
These answers address some of the most common questions patients have after receiving a MacTel type 2 diagnosis, with a focus on helping you make informed decisions about your care.
Yes, and this is precisely why routine eye exams are so valuable. A dilated eye exam combined with OCT imaging can reveal early changes in the retina before you are aware of any vision problems. If you have risk factors such as being over 40, having diabetes, or having high blood pressure, we recommend scheduling regular comprehensive eye exams even when your vision feels normal. Early detection allows your specialist to begin monitoring promptly and make timely treatment decisions.
ENCELTO is designed to slow the ongoing loss of photoreceptors, not to reverse vision that has already been lost to cell damage. Clinical trials focused on measuring the rate at which photoreceptors were lost over time, and treated patients showed significantly less loss than untreated patients. This is why beginning treatment earlier in the disease course, before substantial cell loss has occurred, is generally expected to offer the greatest benefit. Your specialist will evaluate your retina carefully to determine whether and when ENCELTO is appropriate for your situation.
MacTel type 2 does not typically cause total blindness. The disease targets central vision, which is used for tasks like reading, recognizing faces, and driving, but it spares peripheral (side) vision. While central vision loss can be significant and affect quality of life, most patients retain enough peripheral vision to navigate their environment. Low vision rehabilitation can help you adapt and maintain independence even as central vision changes over time.
No, these are two distinct conditions, though both affect the macula and can cause central vision loss. MacTel type 2 involves degeneration of Muller cells and abnormalities in the small blood vessels at the fovea. Age-related macular degeneration involves drusen deposits beneath the retina and follows a different pattern of tissue damage. The two conditions are also treated differently. Specialized imaging, including OCT and fluorescein angiography, allows a retinal specialist to make an accurate diagnosis and recommend the right treatment approach.
The frequency of visits depends on your stage of disease and your treatment plan. During the monitoring phase, follow-up visits with OCT imaging are typically scheduled every three to six months. After ENCELTO implant placement, more frequent visits may be needed initially to assess the implant and observe the retinal response. If you are receiving anti-VEGF injections for neovascularization, appointments may occur every four to eight weeks. Your retinal specialist will build a schedule tailored to your specific needs and adjust it as your condition evolves.
Do not wait for your next scheduled appointment if you notice a sudden or significant change in your vision. A sudden worsening of central vision, a new area of blurriness, flashes of light, or a rapid increase in floaters can indicate a complication that needs urgent evaluation. Contact your retinal specialist right away or go to an emergency eye care facility. Prompt care in these situations can be important for protecting your vision.
See Our Retinal Specialists at EyeCare Consultants of NJ
At EyeCare Consultants of NJ, our retinal specialists are committed to providing thorough, compassionate care for patients with MacTel type 2 and a wide range of other macular and retinal conditions. Serving patients throughout New Jersey from our offices in Edison and Woodland Park, we combine advanced diagnostic technology with individualized treatment planning to help you protect the vision you have. We encourage you to schedule a comprehensive evaluation with our team so we can assess your eye health and guide you toward the best possible care.
Highly recommend Dr. Kayserman. Extremely competent, experienced, highly personable
LS
Dr. Arnett has provided excellent medical attention for my retina eye surgery and has a very professional and positive bedside manner. I would highly recommend him.
R. T
Dr. Larisa Kayzerman is a wonderful doctor. She is very attentive. Doctor maid operation the same day. I'm very satisfied with the result.
Rafail
Dr. Kayserman was gentle, efficient and provided extremely valuable information which was comforting to me. I felt better after seeing her and am looking forward to additional visits.
Lina N.
Dr. Arnett deserves 10 stars. He is the best.
AJ